Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below Fifty Day Moving Average – Should You Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.73 and traded as low as $4.67. Seres Therapeutics shares last traded at $5.00, with a volume of 102,958 shares.

Analyst Ratings Changes

A number of brokerages have issued reports on MCRB. Weiss Ratings lowered Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, HC Wainwright initiated coverage on shares of Seres Therapeutics in a research note on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Price Performance

The company has a fifty day moving average of $5.69 and a two-hundred day moving average of $7.45. The stock has a market capitalization of $49.75 million, a P/E ratio of -2.04 and a beta of 0.20.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%.The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.18 million. As a group, equities research analysts predict that Seres Therapeutics, Inc. will post -6.33 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MCRB. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after buying an additional 21,679 shares during the last quarter. Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 89,995 shares during the last quarter. Bank of America Corp DE grew its position in shares of Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares during the last quarter. Barclays PLC raised its stake in Seres Therapeutics by 427.8% during the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 6,024 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new stake in Seres Therapeutics during the fourth quarter worth about $190,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.